User login
Key clinical point: Upadacitinib continued to demonstrate improvement in clinical manifestations of psoriatic arthritis (PsA) through week 56 in patients with inadequate response to biologic disease-modifying antirheumatic drugs (bDMARDs) with no new adverse events.
Major finding: Consistent with week 24, a higher proportion of patients achieved at least 20% improvement in the American College of Rheumatology criteria with upadacitinib (15 mg, 74.4%; 30 mg, 74.7%) vs. adalimumab (68.5%; P = .046) at week 56. No new safety signals were identified.
Study details: Findings are from an analysis of 1,419 patients with active PsA and inadequate response to at least 1 non-bDMARD who completed 56 weeks of treatment in the phase 3 SELECT-PsA 1 study.
Disclosures: This study was sponsored by AbbVie. The authors reported receiving research grants, honoraria, and consulting fees from or serving as an advisory board member, being an employee, or being shareholders in various companies, including AbbVie.
Source: McInnes IB et al. RMD Open. 2021;7:e001838 (Oct 18). Doi: 10.1136/rmdopen-2021-001838.
Key clinical point: Upadacitinib continued to demonstrate improvement in clinical manifestations of psoriatic arthritis (PsA) through week 56 in patients with inadequate response to biologic disease-modifying antirheumatic drugs (bDMARDs) with no new adverse events.
Major finding: Consistent with week 24, a higher proportion of patients achieved at least 20% improvement in the American College of Rheumatology criteria with upadacitinib (15 mg, 74.4%; 30 mg, 74.7%) vs. adalimumab (68.5%; P = .046) at week 56. No new safety signals were identified.
Study details: Findings are from an analysis of 1,419 patients with active PsA and inadequate response to at least 1 non-bDMARD who completed 56 weeks of treatment in the phase 3 SELECT-PsA 1 study.
Disclosures: This study was sponsored by AbbVie. The authors reported receiving research grants, honoraria, and consulting fees from or serving as an advisory board member, being an employee, or being shareholders in various companies, including AbbVie.
Source: McInnes IB et al. RMD Open. 2021;7:e001838 (Oct 18). Doi: 10.1136/rmdopen-2021-001838.
Key clinical point: Upadacitinib continued to demonstrate improvement in clinical manifestations of psoriatic arthritis (PsA) through week 56 in patients with inadequate response to biologic disease-modifying antirheumatic drugs (bDMARDs) with no new adverse events.
Major finding: Consistent with week 24, a higher proportion of patients achieved at least 20% improvement in the American College of Rheumatology criteria with upadacitinib (15 mg, 74.4%; 30 mg, 74.7%) vs. adalimumab (68.5%; P = .046) at week 56. No new safety signals were identified.
Study details: Findings are from an analysis of 1,419 patients with active PsA and inadequate response to at least 1 non-bDMARD who completed 56 weeks of treatment in the phase 3 SELECT-PsA 1 study.
Disclosures: This study was sponsored by AbbVie. The authors reported receiving research grants, honoraria, and consulting fees from or serving as an advisory board member, being an employee, or being shareholders in various companies, including AbbVie.
Source: McInnes IB et al. RMD Open. 2021;7:e001838 (Oct 18). Doi: 10.1136/rmdopen-2021-001838.